Skip to main content
Erschienen in:

01.12.2016 | original article

Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders

Results from a pilot feasibility trial

verfasst von: Irina Franke, MD, Sarah Thier, MSc, Prof. Dr. med. Anita Riecher-Rössler, MD PhD

Erschienen in: neuropsychiatrie | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

Background

Adherence to evidence-based guidelines is essential for the treatment outcome of psychotic disorders. Previous studies showed that IT-supported pathways are able to increase guideline adherence in psychiatric care. This paper describes a pilot study on the development of an electronic recall-reminder-system (RRS) for supporting guideline-adherent treatment in outpatient care of patients with chronic psychotic disorders and analyses its feasibility.

Methods

Guidelines were integrated in the RRS software M.E.M.O.R.E.S. Software training for the staff was provided. We compared the number of conducted vs. guideline-recommended interventions 6 months before and after implementation. Subsequently both the caregivers’ and the patients’ satisfaction with the RRS was evaluated.

Results

Guideline adherence in general was low and the RRS was barely used. After its implementation a significant increase was observed in chemogram-check-ups and diagnostics regarding cardiovascular risks (esp. ECG). Both patients and professionals described problems with integrating the RRS in their daily routine and questioned the usefulness of the guidelines for chronically ill, although they basically approved its importance and usefulness.

Conclusions

Participants appreciated the idea of supporting guideline adherence with an IT-system, but there seemed to be major obstacles to implementation: caregivers appear to be concerned of being exposed or questioned, technical difficulties might lead to avoidance, and there seems to be a lack of knowledge and awareness about the health risks for individuals with psychotic disorders. Possibly guidelines adapted for the chronically ill would find more acceptance. Technical simplifications and better information should be considered prior to further attempts to implement IT-supported guidelines in order to increase acceptance.
Literatur
1.
Zurück zum Zitat Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde DGPPN (ed.). S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Behandlungsleitlinien Schizophrenie. Darmstadt: Steinkopff; 2006. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde DGPPN (ed.). S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Behandlungsleitlinien Schizophrenie. Darmstadt: Steinkopff; 2006.
2.
Zurück zum Zitat Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. The American journal of psychiatry, 1997. 154(4 Suppl): p. 1–63. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. The American journal of psychiatry, 1997. 154(4 Suppl): p. 1–63.
3.
Zurück zum Zitat NICE Clinical Guidelines. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. In: National Institute of Clinical Excellence (NICE) (ed.). 2010/08/13 ed. Leicester (UK): British Psychological Society; 2009. doi:NBK11681 [bookaccession]. NICE Clinical Guidelines. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. In: National Institute of Clinical Excellence (NICE) (ed.). 2010/08/13 ed. Leicester (UK): British Psychological Society; 2009. doi:NBK11681 [bookaccession].
4.
Zurück zum Zitat Miller, A., et al., The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry, 2004. 65(4): p. 500–8. Miller, A., et al., The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry, 2004. 65(4): p. 500–8.
5.
Zurück zum Zitat Janssen B, et al. Guideline conformity and outcome of inpatient treatment for schizophrenia. A clinical comparison. Nervenarzt. 2005;76(3):315–26.CrossRefPubMed Janssen B, et al. Guideline conformity and outcome of inpatient treatment for schizophrenia. A clinical comparison. Nervenarzt. 2005;76(3):315–26.CrossRefPubMed
6.
Zurück zum Zitat Cullen BA, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr Bull. 2013;39(5):1159–68.CrossRefPubMed Cullen BA, et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr Bull. 2013;39(5):1159–68.CrossRefPubMed
7.
Zurück zum Zitat Kane JM, et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2‑Year Outcomes From the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2015;173(4):362–72.CrossRefPubMed Kane JM, et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2‑Year Outcomes From the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2015;173(4):362–72.CrossRefPubMed
8.
Zurück zum Zitat Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173(1):11–53.CrossRefPubMed Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173(1):11–53.CrossRefPubMed
9.
Zurück zum Zitat Chang C‑K, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry. 2010;10(1):1.CrossRef Chang C‑K, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry. 2010;10(1):1.CrossRef
10.
Zurück zum Zitat Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999. BMJ. 2006;2011(d5422):343. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999. BMJ. 2006;2011(d5422):343.
11.
Zurück zum Zitat Roden DM. Drug-induced prolongation of the QT interval. New Engl J Med. 2004;350(10):1013–22.CrossRefPubMed Roden DM. Drug-induced prolongation of the QT interval. New Engl J Med. 2004;350(10):1013–22.CrossRefPubMed
13.
Zurück zum Zitat Stahl S, Mignon L, Meyer J. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3):171–9.CrossRefPubMed Stahl S, Mignon L, Meyer J. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3):171–9.CrossRefPubMed
14.
Zurück zum Zitat Crump C, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324–33.CrossRefPubMed Crump C, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324–33.CrossRefPubMed
15.
Zurück zum Zitat Kiviniemi M, et al. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5‑year follow-up. Schizophr Res. 2013;150(1):274–80.CrossRefPubMed Kiviniemi M, et al. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5‑year follow-up. Schizophr Res. 2013;150(1):274–80.CrossRefPubMed
16.
Zurück zum Zitat Hennekens CH, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–21.CrossRefPubMed Hennekens CH, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–21.CrossRefPubMed
17.
Zurück zum Zitat Kilbourne AM, et al. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics. 2007;48(5):412–7.CrossRefPubMed Kilbourne AM, et al. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics. 2007;48(5):412–7.CrossRefPubMed
18.
Zurück zum Zitat Arbus C, et al. Health management of older persons with chronically medicated psychotic disorders: the results of a. survey France Int Psychogeriatrics/ipa. 2012;24(3):496–502.CrossRef Arbus C, et al. Health management of older persons with chronically medicated psychotic disorders: the results of a. survey France Int Psychogeriatrics/ipa. 2012;24(3):496–502.CrossRef
19.
Zurück zum Zitat Hert M de, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24.CrossRefPubMed Hert M de, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24.CrossRefPubMed
20.
Zurück zum Zitat Hert M de, Peuskens J, Winkel R van, Mortality in patients with schizophrenia. Lancet, 2009. 374(9701): p. 1591; author reply 1592–3. Hert M de, Peuskens J, Winkel R van, Mortality in patients with schizophrenia. Lancet, 2009. 374(9701): p. 1591; author reply 1592–3.
21.
Zurück zum Zitat Correll CU, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–63.CrossRefPubMed Correll CU, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–63.CrossRefPubMed
22.
Zurück zum Zitat Vancampfort D, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–47.CrossRefPubMedPubMedCentral Vancampfort D, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–47.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cochrane LJ, et al. Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. J Contin Educ Health Prof. 2007;27(2):94–102.CrossRefPubMed Cochrane LJ, et al. Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. J Contin Educ Health Prof. 2007;27(2):94–102.CrossRefPubMed
24.
Zurück zum Zitat Shcherbatykh I, et al. Methodologic issues in health informatics trials: the complexities of complex interventions. J Am Med Inform Assoc. 2008;15(5):575–80.CrossRefPubMedPubMedCentral Shcherbatykh I, et al. Methodologic issues in health informatics trials: the complexities of complex interventions. J Am Med Inform Assoc. 2008;15(5):575–80.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Kilbourne AM. E‑health and the transformation of mental health care. Psychiatr Serv. 2012;63(11):1059.CrossRefPubMed Kilbourne AM. E‑health and the transformation of mental health care. Psychiatr Serv. 2012;63(11):1059.CrossRefPubMed
26.
Zurück zum Zitat Hilty, D.M., et al., The effectiveness of telemental health: a 2013 review. Telemed J E Health, 2013. 19(6): p. 444–54. Hilty, D.M., et al., The effectiveness of telemental health: a 2013 review. Telemed J E Health, 2013. 19(6): p. 444–54.
27.
Zurück zum Zitat Godemann F, et al. Guideline compliance in the treatment of schizophrenic patients. Introduction of a computer-assisted treatment pathway. Nervenarzt. 2010;81(5):584–93.CrossRefPubMed Godemann F, et al. Guideline compliance in the treatment of schizophrenic patients. Introduction of a computer-assisted treatment pathway. Nervenarzt. 2010;81(5):584–93.CrossRefPubMed
28.
Zurück zum Zitat van Dijk MK, Oosterbaan DB, Verbraak MJ, van Balkom AJ. The effectiveness of adhering to clinical-practice guidelines for anxiety disorders in secondary mental health care: the results of a cohort study in the Netherlands. J Eval Clin Pract. 2013;19(5):791–7.PubMed van Dijk MK, Oosterbaan DB, Verbraak MJ, van Balkom AJ. The effectiveness of adhering to clinical-practice guidelines for anxiety disorders in secondary mental health care: the results of a cohort study in the Netherlands. J Eval Clin Pract. 2013;19(5):791–7.PubMed
29.
Zurück zum Zitat Markkula N, Alvarado R, Minoletti A. Adherence to guidelines and treatment compliance in the Chilean national program for first-episode schizophrenia. Psychiatr Serv. 2011;62(12):1463–9.CrossRefPubMed Markkula N, Alvarado R, Minoletti A. Adherence to guidelines and treatment compliance in the Chilean national program for first-episode schizophrenia. Psychiatr Serv. 2011;62(12):1463–9.CrossRefPubMed
30.
Zurück zum Zitat Benkert, O., Hippius, H, (eds.), Kompendium der Psychiatrischen Pharmakotherapie. 2011, Heidelberg: Springer Medizin Verlag Benkert, O., Hippius, H, (eds.), Kompendium der Psychiatrischen Pharmakotherapie. 2011, Heidelberg: Springer Medizin Verlag
32.
Zurück zum Zitat Riecher-Rössler A, Aston J, Ventura J, Merlo M, Borgwardt S, Gschwandtner U et al. [The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity]. Fortschr Neurol Psychiatr. 2008;76(4):207–16.CrossRefPubMed Riecher-Rössler A, Aston J, Ventura J, Merlo M, Borgwardt S, Gschwandtner U et al. [The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity]. Fortschr Neurol Psychiatr. 2008;76(4):207–16.CrossRefPubMed
33.
Zurück zum Zitat Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. J Ment Health. 2002;11(2):191–8.CrossRefPubMed Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. J Ment Health. 2002;11(2):191–8.CrossRefPubMed
34.
Zurück zum Zitat Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241–7.CrossRefPubMed Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241–7.CrossRefPubMed
Metadaten
Titel
Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders
Results from a pilot feasibility trial
verfasst von
Irina Franke, MD
Sarah Thier, MSc
Prof. Dr. med. Anita Riecher-Rössler, MD PhD
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
neuropsychiatrie / Ausgabe 4/2016
Print ISSN: 0948-6259
Elektronische ISSN: 2194-1327
DOI
https://doi.org/10.1007/s40211-016-0202-1

Weitere Artikel der Ausgabe 4/2016

neuropsychiatrie 4/2016 Zur Ausgabe

kultur im kontext

kultur im kontext